$1.01 Billion is the total value of RA Capital Management's 57 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 35.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGMO | SANGAMO BIOSCIENCES INCcall | $94,080,000 | +2.7% | 6,000,000 | 0.0% | 9.34% | -5.1% | |
| ACHN | Buy | ACHILLION PHARMACEUTICALS INC | $80,926,000 | -1.4% | 8,207,530 | +22.5% | 8.04% | -8.9% |
| DYAX | Sell | DYAX CORP | $70,498,000 | +1.4% | 4,207,594 | -14.9% | 7.00% | -6.3% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS | $62,547,000 | -27.0% | 6,926,617 | -1.8% | 6.21% | -32.6% |
| RGLS | Sell | REGULUS THERAPEUTICS INC | $60,826,000 | -20.0% | 3,590,688 | -24.3% | 6.04% | -26.1% |
| DRNA | DICERNA PHARMACEUTICALS INC | $58,359,000 | +45.9% | 2,428,571 | 0.0% | 5.80% | +34.8% | |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $58,318,000 | – | 2,600,000 | +100.0% | 5.79% | – |
| TGTX | Sell | TG THERAPEUTICS INC | $48,377,000 | -8.8% | 3,125,149 | -6.7% | 4.80% | -15.8% |
| CHRS | COHERUS BIOSCIENCES INC | $47,563,000 | +87.4% | 1,555,355 | 0.0% | 4.72% | +73.1% | |
| TKMR | New | TEKMIRA PHARMACEUTICALS CORP | $47,400,000 | – | 2,714,800 | +100.0% | 4.71% | – |
| XNCR | Buy | XENCOR INC | $32,929,000 | +46.7% | 2,149,423 | +53.6% | 3.27% | +35.6% |
| ZFGN | ZAFGEN INC | $29,033,000 | +28.4% | 732,960 | 0.0% | 2.88% | +18.7% | |
| BLUE | Sell | BLUEBIRD BIO INC | $24,200,000 | -47.9% | 200,379 | -60.4% | 2.40% | -51.8% |
| BLCM | BELLICUM PHARMACEUTICALS INC | $23,782,000 | +154.7% | 1,026,402 | 0.0% | 2.36% | +135.5% | |
| ZSPH | ZS PHARMA INC | $23,753,000 | +1.2% | 564,483 | 0.0% | 2.36% | -6.5% | |
| SGMO | SANGAMO BIOSCIENCES INC | $19,133,000 | +3.1% | 1,220,209 | 0.0% | 1.90% | -4.8% | |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $17,760,000 | – | 1,023,652 | +100.0% | 1.76% | – |
| JUNO | JUNO THERAPEUTICS INC | $16,985,000 | +16.2% | 280,000 | 0.0% | 1.69% | +7.4% | |
| OMER | New | OMEROS CORP | $16,500,000 | – | 749,000 | +100.0% | 1.64% | – |
| PRTO | PROTEON THERAPEUTICS INC | $14,538,000 | +11.8% | 1,250,000 | 0.0% | 1.44% | +3.4% | |
| AGRX | New | AGILE THERAPEUTICS INC | $13,523,000 | – | 1,458,792 | +100.0% | 1.34% | – |
| NVAX | Sell | NOVAVAX INC | $11,836,000 | -38.4% | 1,431,232 | -55.8% | 1.18% | -43.1% |
| TXMD | Sell | THERAPEUTICSMD INC | $10,166,000 | -28.9% | 1,680,395 | -47.7% | 1.01% | -34.2% |
| ARRY | New | ARRAY BIOPHARMA INC | $10,005,000 | – | 1,357,584 | +100.0% | 0.99% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $9,996,000 | – | 660,000 | +100.0% | 0.99% | – |
| OREX | New | OREXIGEN THERAPEUTICS INC | $9,288,000 | – | 1,186,229 | +100.0% | 0.92% | – |
| TENX | TENAX THERAPEUTICS INC | $8,705,000 | -15.1% | 2,670,300 | 0.0% | 0.86% | -21.6% | |
| TRVN | Sell | TREVENA INC | $8,642,000 | -51.4% | 1,325,407 | -55.4% | 0.86% | -55.1% |
| SCMP | New | SUCAMPO PHARMACEUTICALS INCcl a | $7,002,000 | – | 450,000 | +100.0% | 0.70% | – |
| VICL | Buy | VICAL INC | $6,637,000 | +1.9% | 7,024,274 | +13.2% | 0.66% | -5.9% |
| AKBA | AKEBIA THERAPEUTICS INC | $6,637,000 | -4.5% | 597,363 | 0.0% | 0.66% | -11.8% | |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $6,561,000 | -27.1% | 1,504,776 | -39.2% | 0.65% | -32.6% |
| SCYX | Sell | SCYNEXIS INC | $6,550,000 | -21.9% | 789,097 | -6.1% | 0.65% | -27.9% |
| EARS | AURIS MED HLDG AG | $5,029,000 | +37.2% | 940,000 | 0.0% | 0.50% | +26.6% | |
| VSAR | VERSARTIS INC | $4,248,000 | -18.2% | 231,267 | 0.0% | 0.42% | -24.4% | |
| TROV | New | TROVAGENE INC | $4,047,000 | – | 594,200 | +100.0% | 0.40% | – |
| BOTA | Buy | BIOTA PHARMACEUTIALS INC | $3,229,000 | +4.6% | 1,403,853 | +1.8% | 0.32% | -3.3% |
| RMTI | Sell | ROCKWELL MED INC | $2,735,000 | -62.3% | 250,207 | -64.6% | 0.27% | -65.1% |
| TTOO | T2 BIOSYSTEMS INC | $2,142,000 | -19.3% | 138,002 | 0.0% | 0.21% | -25.3% | |
| OCRX | OCERA THERAPEUTICS INC | $1,966,000 | -26.1% | 417,476 | 0.0% | 0.20% | -31.8% | |
| ONTY | New | ONCOTHYREON INC | $1,900,000 | – | 1,165,765 | +100.0% | 0.19% | – |
| AGIO | AGIOS PHARMACEUTICALS INC | $1,660,000 | -15.8% | 17,600 | 0.0% | 0.16% | -22.2% | |
| NLNK | NEWLINK GENETICS CORP | $1,641,000 | +37.6% | 30,000 | 0.0% | 0.16% | +27.3% | |
| PTCT | PTC THERAPEUTICS INC | $1,570,000 | +17.5% | 25,800 | 0.0% | 0.16% | +8.3% | |
| MACK | MERRIMACK PHARMACEUTICALS IN | $1,383,000 | +5.2% | 116,400 | 0.0% | 0.14% | -2.8% | |
| RGEN | REPLIGEN CORP | $1,366,000 | +53.3% | 45,000 | 0.0% | 0.14% | +41.7% | |
| TSRO | New | TESARO INC | $1,349,000 | – | 23,500 | +100.0% | 0.13% | – |
| ALKS | ALKERMES PLC | $1,171,000 | +4.2% | 19,200 | 0.0% | 0.12% | -4.1% | |
| WGBS | Sell | WAFERGEN BIO-SYSTEMS INC | $1,157,000 | -31.1% | 255,400 | -54.4% | 0.12% | -36.5% |
| REGN | REGENERON PHARMACEUTICALS | $1,106,000 | +10.0% | 2,450 | 0.0% | 0.11% | +1.9% | |
| BIIB | BIOGEN INC | $1,098,000 | +24.3% | 2,600 | 0.0% | 0.11% | +14.7% | |
| CELG | CELGENE CORP | $1,003,000 | +3.1% | 8,700 | 0.0% | 0.10% | -4.8% | |
| AMGN | AMGEN INC | $943,000 | +0.3% | 5,900 | 0.0% | 0.09% | -6.9% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $890,000 | +2.7% | 27,300 | 0.0% | 0.09% | -5.4% | |
| CLDN | CELLADON CORP | $775,000 | -3.0% | 40,900 | 0.0% | 0.08% | -10.5% | |
| KERX | KERYX BIOPHARMACEUTICALS INC | $754,000 | -10.0% | 59,200 | 0.0% | 0.08% | -16.7% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $732,000 | +24.7% | 3,100 | 0.0% | 0.07% | +15.9% | |
| KYTH | Exit | KYTHERA BIOPHARMACEUTICALS | $0 | – | -22,750 | -100.0% | -0.08% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -2,500,000 | -100.0% | -0.63% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -310,554 | -100.0% | -1.50% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -970,600 | -100.0% | -2.17% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INcall | $0 | – | -2,500,000 | -100.0% | -3.29% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCcall | $0 | – | -1,000,000 | -100.0% | -3.41% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2015-07-06
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S - ADR | 35 | Q3 2023 | 25.5% |
| WAVE LIFE SCIENCES PTE LTD | 32 | Q3 2023 | 26.3% |
| TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
| ZOGENIX INC | 26 | Q4 2021 | 9.5% |
| BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
| DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
| RHYTHM PHARMACEUTICALS INC | 22 | Q3 2023 | 4.4% |
| ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
| KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 6.8% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | September 22, 2023 | 6,940,000 | 6.2% |
| BELLUS Health Inc.Sold out | August 14, 2023 | 0 | 0.0% |
| Kinnate Biopharma Inc.Sold out | August 14, 2023 | 0 | 0.0% |
| Vor Biopharma Inc. | August 11, 2023 | 22,780,343 | 33.7% |
| DICE Therapeutics, Inc.Sold out | August 09, 2023 | 0 | 0.0% |
| Acumen Pharmaceuticals, Inc. | July 25, 2023 | 14,981,618 | 25.9% |
| Talaris Therapeutics, Inc. | July 06, 2023 | 2,333,175 | 5.5% |
| Aerovate Therapeutics, Inc. | June 27, 2023 | 8,293,148 | 30.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | June 12, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp VSold out | May 15, 2023 | 0 | 0.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-25 |
| 4 | 2024-04-15 |
| 4 | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-12 |
| SC 13G | 2024-04-12 |
| SC 13D/A | 2024-04-11 |
| SC 13G | 2024-04-11 |
| 4 | 2024-04-04 |
| SC 13G | 2024-04-04 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.